Ardelyx Q3 product revenue rises 19%, loss narrows
ARDX•Ardelyx reported third-quarter product revenue of $125.46 million, up 19% year over year, and a net loss of $737,000. The company reiterated its 2026 revenue guidance for IBSRELA and XPHOZAH and expects operating expenses below $500 million.
1. Quarterly results
Ardelyx's third-quarter product revenue rose 19% year over year to $125.46 million. The company reported a net loss of $737,000 and operating income of $4.02 million.
2. Product performance and outlook
IBSRELA revenue grew 23% year over year, driven by increases in total writers and prescriptions, while XPHOZAH revenue rose 7%. Ardelyx reiterated 2026 IBSRELA revenue guidance of $350 million to $370 million and XPHOZAH guidance of $110 million to $120 million, and expects 2026 operating expenses to remain below $500 million.
3. Trial enrollment
The company completed enrollment ahead of schedule in its Phase 3 ACCEL trial for chronic idiopathic constipation.
